Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Moderna (MRNA) will present late-breaking and additional clinical data on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, at the ESMO Congress 2026 in Madrid from October 23-27.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moderna (MRNA) will present late-breaking and additional clinical data on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, at the ESMO Congress 2026 in Madrid from October 23-27.
The company’s Phase 3 melanoma study INTerpath-001 (intismeran plus pembrolizumab vs pembrolizumab alone) is scheduled in the Presidential Symposium on Saturday, October 24, at 4:30 PM CEST / 10:30 AM EDT. Two poster sessions will cover a Phase I study in resectable pancreatic ductal adenocarcinoma (Sunday, October 25, 12:00-12:45 PM CET) and the Phase 3 INTerpath-014 trial in high-risk stage I NSCLC (Monday, October 26, 12:00-12:45 PM CET). Intismeran autogene is jointly developed by Moderna and Merck (MSD outside the US and Canada).
Moderna will also host a live investor webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT, with a replay available for at least 30 days.
Details
News Market Reaction – MRNA
On Sep 21, the day this news came out, MRNA closed 12.27% above the previous close. Argus tracked a peak move of +10.3% during that session. Our momentum scanner recorded 147 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 21 session.
Key Figures
- Accepted abstracts
- 3 abstracts
- ESMO Congress 2026
- Presidential Symposium presentation
- October 24, 2026
- INTerpath-001 Phase 3 study
- Pancreatic cancer poster
- October 25, 2026
- Phase I study
- NSCLC poster
- October 26, 2026
- INTerpath-014 Phase 3 study
Key Terms
neoantigen therapy medical
folfirinox medical
nsclc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESS Newswire / September 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain.
The presentation details are as follows:
Presidential Symposium:
- LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
Session Type/Title: Presidential Symposium
Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT
Presenter: Georgina V. Long (Sydney, Australia, NSW)
Poster Presentations:
- Abstract 3151P: Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study
Session Type/Title: Poster - Pancreatic cancer
Date & Time: Sunday, October 25, 12:00-12:45 PM CET
Presenter: David J. Pinato (London, United Kingdom) - Abstract 2550TiP: INTerpath-014: A Phase 3 Study of Adjuvant Intismeran Autogene (Intismeran) Plus Subcutaneous Pembrolizumab (Pembro SC) or Intismeran Monotherapy vs Placebo in Completely Resected High-Risk Stage I NSCLC
Session Type/Title: Poster - NSCLC, early stage
Date & Time: Monday, October 26, 12:00-12:45 PM CET
Presenter: Charu Aggarwal (Philadelphia, United States of America)
Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
Moderna Investor Event
Moderna will host a live webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When and where will the Phase 3 INTerpath-001 melanoma data on intismeran autogene be presented?
The INTerpath-001 Phase 3 melanoma study of intismeran autogene plus pembrolizumab versus pembrolizumab alone will be presented in the ESMO 2026 Presidential Symposium on Saturday, October 24, at 4:30 PM CEST / 10:30 AM EDT in Madrid, Spain.
What other cancer indications for intismeran autogene will be discussed at ESMO 2026?
Additional presentations cover a Phase I study of adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma (poster session on Sunday, October 25, 12:00-12:45 PM CET) and the Phase 3 INTerpath-014 adjuvant study in completely resected high-risk stage I NSCLC (poster session on Monday, October 26, 12:00-12:45 PM CET).